Literature DB >> 7574462

Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer's disease.

H Arai1, M Terajima, M Miura, S Higuchi, T Muramatsu, N Machida, H Seiki, S Takase, C M Clark, V M Lee.   

Abstract

Cerebrospinal fluid from 70 patients with Alzheimer's disease (AD) and 96 patients with non-AD neurological diseases as well as 19 normal control subjects was surveyed by sandwich enzyme-linked immunosorbent assay to quantitate levels of the microtubule-associated protein tau in cerebrospinal fluid. The tau level was significantly increased in AD patients as compared with that in patients with non-AD neurological diseases and control subjects. Increased tau levels were found irrespective of age at onset, apolipoprotein E genotype, and clinical stage. Western blots of AD cerebrospinal fluid proteins revealed two to three tau-immunoreactive bands with an apparent molecular mass between 50 and 65 kd consistent with phosphorylated cerebrospinal fluid tau. Taken together, our results suggest that cerebrospinal fluid tau might reflect the progressive accumulation of altered tau due to the progressive death of neurons in the AD brain, and that the enzyme-linked immunosorbent assay of cerebrospinal fluid tau may prove to be a reliable and early diagnostic test for AD.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7574462     DOI: 10.1002/ana.410380414

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  61 in total

1.  Both total and phosphorylated tau are increased in Alzheimer's disease.

Authors:  M Sjögren; P Davidsson; M Tullberg; L Minthon; A Wallin; C Wikkelso; A K Granérus; H Vanderstichele; E Vanmechelen; K Blennow
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-05       Impact factor: 10.154

2.  The dynamics of Alzheimer's disease biomarkers in the Alzheimer's Disease Neuroimaging Initiative cohort.

Authors:  A Caroli; G B Frisoni
Journal:  Neurobiol Aging       Date:  2010-06-11       Impact factor: 4.673

3.  Cerebrospinal fluid analysis differentiates between relapsing-remitting and secondary progressive multiple sclerosis.

Authors:  P J Jongen; K J Lamers; W H Doesburg; W A Lemmens; O R Hommes
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-10       Impact factor: 10.154

4.  Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly.

Authors:  Anne M Fagan; Denise Head; Aarti R Shah; Daniel Marcus; Mark Mintun; John C Morris; David M Holtzman
Journal:  Ann Neurol       Date:  2009-02       Impact factor: 10.422

Review 5.  Cerebrospinal fluid protein biomarkers for Alzheimer's disease.

Authors:  Kaj Blennow
Journal:  NeuroRx       Date:  2004-04

Review 6.  Biomarkers for Alzheimer disease in cerebrospinal fluid, urine, and blood.

Authors:  Anders Lönneborg
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

7.  A sandwich enzyme immunoassay for measuring AD7C-NTP as an Alzheimer's disease marker: AD7C test.

Authors:  K Ghanbari; H A Ghanbari
Journal:  J Clin Lab Anal       Date:  1998       Impact factor: 2.352

8.  Multiple mechanisms of extracellular tau spreading in a non-transgenic tauopathy model.

Authors:  Meghan N Le; Wonhee Kim; Sangmook Lee; Ann C McKee; Garth F Hall
Journal:  Am J Neurodegener Dis       Date:  2012-11-25

Review 9.  Emerging biomarkers in cognition.

Authors:  Meredith Wicklund; Ronald C Petersen
Journal:  Clin Geriatr Med       Date:  2013-11       Impact factor: 3.076

10.  Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade.

Authors:  Clifford R Jack; David S Knopman; William J Jagust; Leslie M Shaw; Paul S Aisen; Michael W Weiner; Ronald C Petersen; John Q Trojanowski
Journal:  Lancet Neurol       Date:  2010-01       Impact factor: 44.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.